Detailed Information on Publication Record
2020
Recurrent gene mutations detected in canine mast cell tumours by next generation sequencing
VOZDOVA, M., S. KUBICKOVA, Karol PÁL, J. FROHLICH, P. FICTUM et. al.Basic information
Original name
Recurrent gene mutations detected in canine mast cell tumours by next generation sequencing
Authors
VOZDOVA, M., S. KUBICKOVA, Karol PÁL (703 Slovakia, guarantor, belonging to the institution), J. FROHLICH, P. FICTUM and J. RUBES
Edition
VETERINARY AND COMPARATIVE ONCOLOGY, HOBOKEN, WILEY, 2020, 1476-5810
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
40301 Veterinary science
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.613
RIV identification code
RIV/00216224:14740/20:00118346
Organization unit
Central European Institute of Technology
UT WoS
000590128500007
Keywords in English
cancer; dog; GNB1; KIT; mast cell tumour; mutation; next generation sequencing; whole exome sequencing
Tags
International impact, Reviewed
Změněno: 15/10/2024 09:21, Ing. Martina Blahová
Abstract
V originále
Genetic causes of canine mast cell tumours (MCTs), except for mutations in the KIT gene detected in some MCTs, are generally unknown. We used whole exome sequencing to reveal mutation spectra in canine MCTs. We detected somatic mutations in 87 genes including 10 genes recognized as human cancer drivers. Besides KIT, 14 other genes were recurrently mutated. Subsequently, we performed next generation sequencing of a panel of 50 selected genes in additional MCT samples. In this group, the most frequently altered gene was GNB1 showing a recurrent dinucleotide substitution at position of Gly116 in 30% of the MCT samples (n = 6/20) and Ile80 substitution accompanied by a splice region mutation in one case. We extended the study by analysis of the above mentioned GNB1 regions in additional MCT samples by Sanger sequencing, and assessed the overall prevalence of GNB1 mutations to 17.3% (n = 14/81), which is similar to the prevalence of KIT alterations. Our results indicate that GNB1 mutations are probably involved in canine MCT pathogenesis in both cutaneous and subcutaneous MCT cases. As opposed to KIT alterations, the presence of GNB1 mutations did not negatively affect survival times, and our data even showed a trend towards positive prognosis. If our results are confirmed in a larger number of MCTs, an extension of molecular testing of canine MCTs by GNB1 analysis would help to refine the molecular stratification of MCTs, and become useful for targeted treatment strategies.
Links
LQ1601, research and development project |
| ||
90091, large research infrastructures |
|